Strategic Investment Fuels FDA Regulatory Path and Global Commercialization; Company to Showcase Technology at AUA 2026 BOSTON and YOKNEAM, Israel, May 14, 2026 /PRNewswire/ — Butterfly Medical, developer of a proprietary non-surgical solution for BPH (benign prostatic hyperplasia), today announced the successful completion of its Series C funding round, raising $21 million. The strong […]
Radiology
Ardent Health and Fujifilm Partner to Deliver Synapse Enterprise Imaging Across Radiology and Cardiology Throughout All Facilities
BRENTWOOD, Tenn. & LEXINGTON, Mass.–(BUSINESS WIRE)–Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., has partnered with FUJIFILM Healthcare Americas Corporation to implement its Synapse® enterprise imaging solutions across Ardent’s acute care hospital footprint across six states. Fujifilm’s Synapse Enterprise Imaging solutions will provide Ardent clinicians with a single, holistic view of patient imaging data across various d
AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced two-year results from the PRESERVE pivotal trial (NCT04972097) demonstrating durable oncologic control and a sustained safety profile for the NanoKnife System in the focal ablation of intermediate-risk prostate cancer. The data will be discus
BD Reimagines Central Line Insertion, Advancing Leadership in Patient Safety Through Breakthrough Vascular Access Technology
With the launch of CentroVena One™, BD brings a first‑of‑its‑kind insertion system to market that simplifies central line placement for clinicians and enhances care in acute settings FRANKLIN LAKES, N.J., April 29, 2026 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a…
NorthStar Mapping System Now Commercially Available in the United States
MINNEAPOLIS–(BUSINESS WIRE)– #WeareiMR–Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR) is pleased to announce the U.S. commercial launch of its NorthStar® Mapping System. As the first and only cardiac mapping and guidance system designed specifically to harness the power of magnetic resonance (MR) imaging to see the heart throughout a minimally-invasive interventional procedure, NorthStar brings the field of interventional MR (iMR) to life. NorthStar provides physicians with an entirely ne
HOPPR Expands Medical Imaging AI Portfolio with Chest Radiography Narrative Model
New vision-language model translates chest X-rays into descriptive, structured text, giving developers a foundation for radiology workflow applications. The HOPPR™ MC Chest Radiography Narrative Model is a Vision Language Model that translates chest X-rays into structured narrative text…
Nanox Signs Distribution Agreement with Radiology Oncology Systems to Expand Nanox.ARC Adoption in the United States
Expands Nanox’s growing network of U.S. distribution partnerships
First Peer-Reviewed Study to Evaluate AI-Generated Impressions Demonstrates Radiologist Preference for Domain-Specific Versus General Models
Multi-stakeholder evaluation finds domain-specific AI better aligns with clinical workflows, while general-purpose LLMs fall short in usability and clarity SAN FRANCISCO, Calif., April 21, 2026 /PRNewswire/ — Rad AI, the leader in AI-powered radiology workflow solutions, announced the…
Bunkerhill Health Secures CMS Reimbursement Pathway for AI Cardiovascular Analysis, Receives FDA Clearance for the First AI Algorithms to Evaluate Coronary and Aortic Valve Calcium on Contrast-Enhanced Chest CTs
SAN FRANCISCO–(BUSINESS WIRE)–Bunkerhill Health, an agentic AI company building healthcare’s system of action, today announced that the Centers for Medicare and Medicaid Services (CMS) has established a new national billing code and associated payment under the Hospital Outpatient Prospective Payment System (OPPS) for algorithmic analysis of coronary artery calcium (CAC) and aortic valve calcium (AVC) on chest CT scans, effective April 1, 2026. The company also received U.S. Food and Drug Adm
Sirtex Medical’s DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC
The DOORwaY90 study met its prespecified co-primary endpoints, achieving a best overall response rate (ORR) of 99% WOBURN, Mass., April 13, 2026 /PRNewswire/ — Sirtex Medical (“Sirtex”), a leading manufacturer of interventional oncology and embolization solutions, today announced…



